Mirvie Raises $60M in Series B Funding

Mirvie, a South San Francisco, Calif.- based leader in predicting unexpected pregnancy complications, raised a total of $90m to date following the close of its $60m Series B funding.

The financing was led by Decheng Capital with additional funding from funds and accounts managed by BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield as well as a debt facility with Comerica Bank. Seven-time Olympic gold-medalist and maternal health advocate Allyson Felix also joined the financing as a new investor.

The funding will support the company’s continued clinical and commercial development of the proprietary Mirvie RNA platform, which predicts preeclampsia and preterm birth months before they happen by revealing the underlying biology of each pregnancy.

Led by Maneesh Jain, Co-Founder and CEO, Mirvie provides an RNA platform that can reveal the distinct underlying biological causes of unexpected complications that were only hypothesized before. It enables tailoring existing interventions to patients based on their unique biology and allows the development of new interventions directly targeting their distinct causes. Mirvie is conducting ongoing clinical research to validate existing peer-reviewed evidence, to enhance the RNA platform performance, and to improve the understanding of other pregnancy complications.

Mirvie is shaping the future of pregnancy health by providing women, expecting parents and their doctors with an early detection window to intervene before unexpected pregnancy complications become a crisis. One in five pregnancies is impacted by complications that lead to lifelong health consequences for expecting parents and babies. The proprietary Mirvie RNA platform uses a simple blood test to reveal vital information about a pregnancy’s unique biology and detect complications months before they occur. The idea for Mirvie was sparked by the personal experience of one of the founders whose daughter was born prematurely. Mirvie’s team of world-class scientists and entrepreneurs have brought to market category-first, non-invasive tests in both women’s health and in early cancer detection, used by millions today.